NCT02837991 2020-06-04A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell CarcinomaCelldex TherapeuticsPhase 1 Terminated16 enrolled